Microvascular outcomes in type 2 diabetes

Affiliations

¹ CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, Netherlands; Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, 6202 AZ, Netherlands. Electronic address: cda.stehouwer@mumc.nl.
² CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, Netherlands; Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, 6202 AZ, Netherlands.

Comment

Coen D A Stehouwer et al. Lancet Diabetes Endocrinol. 2017 Aug.

. 2017 Aug;5(8):579.

doi: 10.1016/S2213-8587(17)30187-0.

¹ CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, Netherlands; Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, 6202 AZ, Netherlands. Electronic address: cda.stehouwer@mumc.nl.
² CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, Netherlands; Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, 6202 AZ, Netherlands.

No abstract available

Comment in

Microvascular outcomes in type 2 diabetes - Authors' reply.
Zoungas S, Gerstein HC, Holman RR, Reaven P, Woodward M, Arima H, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) writing group. Zoungas S, et al. Lancet Diabetes Endocrinol. 2017 Aug;5(8):580. doi: 10.1016/S2213-8587(17)30185-7. Lancet Diabetes Endocrinol. 2017. PMID: 28732664 No abstract available.

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.
Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, Hayward RA, Craven T, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) group. Zoungas S, et al. Lancet Diabetes Endocrinol. 2017 Jun;5(6):431-437. doi: 10.1016/S2213-8587(17)30104-3. Epub 2017 Mar 30. Lancet Diabetes Endocrinol. 2017. PMID: 28365411